- Posted Thursday September 9, 2021
Karen Quintos one of 5 across City of Hope enterprise whose skillsets will be valuable assets to the existing boards of directors, which are filled with accomplished leaders in diverse fields
PHOENIX, Ariz., and DUARTE, Calif. — Sept. 9, 2021 — Technology executive, Karen Hughes Quintos, executive vice president and the first-ever chief customer officer (retired) at Dell Technologies, has been named to the Board of Directors of the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, which announced today’s appointments.
City of Hope, a world-renowned research and treatment center for cancer and diabetes, also announced the appointment of four other new members to the boards of directors of two other entities within the City of Hope enterprise: Beckman Research Institute of City of Hope, and City of Hope National Medical Center, which is a National Cancer Institute-designated comprehensive cancer center.
Quintos is a seasoned leader in the highly competitive area of computing for Dell, an American multinational computer technology company that has been instrumental in changing the digital landscape. She has been responsible for the company’s social impact strategy and programs focused on sustainability, diversity and inclusion. Quintos is a passionate advocate for women, especially the advancement of women in the technology industry. In 2015, she was listed among the most influential chief marketing officers in the world by Forbes. She earned a master’s degree in marketing and international business from New York University.
“We are pleased to welcome Ms. Quintos to the TGen Board of Directors,” said TGen President and Research Director, Jeffrey M. Trent, Ph.D., F.A.C.M.G.G. “Her experience, expertise, insights and passion for advocacy will serve TGen well as the future of biomedical research and genomic-based precision medicine continues to influence how we study, treat and prevent disease.”
TGen is a pioneer in the field of translational research, the process of rapidly moving research toward the benefit of patients with neurological disorders, cancer, diabetes and infectious diseases. TGen physicians and scientists specialize in genomic testing and precision medicine, where a deep understanding of the human genome is applied to the study of disease. They use the information learned from a patient’s own genome to help physicians select the right treatment for that individual.
Beckman Research Institute of City of Hope is an academic research center that provides City of Hope with the foundational expertise required to be a leader in the fight against deadly diseases and to develop lifesaving drug discoveries, such as the technology that led to the development of synthetic human insulin and the cancer-fighting drugs Herceptin, Rituxan, Erbitux and Avastin. Its new board members are biotechnology leader Charlotte Hubbert, Ph.D., medical device and health care services executive Julian Husbands, M.D., and financial and business leader Arthur “Emmet” Stephenson Jr.
City of Hope National Medical Center operates a 217-licensed bed acute care hospital that treats people with cancer and other life-threatening diseases. It is a leader in cell therapies, and bone marrow and stem cell transplants. Senior health care executive Adrienne White-Faines has joined the City of Hope National Medical Center board of directors.
“City of Hope welcomes our newest board members, who bring deep and extensive expertise in research, technology, health care program development, biotechnology venture investment, and financial and business management,” said Robert Stone, president and CEO of City of Hope and the Helen and Morgan Chu Chief Executive Officer Distinguished Chair. “Their experience, insight and leadership will help further City of Hope’s mission to eliminate cancer and diabetes, as well as advance our leading clinical care and research model. Strong governance has always been foundational to our success in delivering a uniquely transformative and comprehensive cancer program as we accelerate the delivery of our scientific and medical breakthroughs to the patients, families and communities who need us.”
Hubbert is senior director of business development & strategic alliances at NanoString, a biotech company that specializes in the development of cancer diagnostics tools. She has more than 15 years of basic science research experience and over 10 years of biotech venture experience across a broad range of sectors, therapeutic modalities and disease stages. Hubbert was previously partner and head of Gates Foundation Venture Capital, a $500 million initiative at the Bill and Melinda Gates Foundation Strategic Investment Fund. In that role, she oversaw investing in innovative technologies that supported the foundation’s programs in global health and agriculture. She received a bachelor’s degree in microbiology from the University of Washington and a doctorate degree in molecular cancer biology from Duke University. In 2016, she was honored as Fierce Woman in Biopharma by FiercePharma and as a Leading Woman in Life Sciences by Life Science Washington.
Husbands is vice president of engagement and commercial operations at Equinox Ophthalmic, which is revolutionizing the treatment of glaucoma and other progressive eye diseases through research and technology innovation. He earned his medical degree from, and completed his general surgery residency at, the University of Pennsylvania.
Stephenson is founder and senior partner of Stephenson Ventures, a private equity firm. He founded internet publishing firm Domain.com Inc. and for 22 years served as director of Danaher, a global science and technology innovator committed to helping customers solve complex challenges and improve worldwide quality of life. Stephenson earned a Master of Business Administration from Harvard Business School and received the Albert Einstein Technology Medal in 1999.
White-Faines is chief strategy officer at the American College of Physicians, a diverse community of internal medicine specialists and subspecialists united by a commitment to excellence. She brings extensive experience in operations administration, program design and business development, and medical education. White-Faines was formerly chief executive officer at the American Osteopathic Association and vice president and chief health officer at the American Cancer Society, Illinois Division. She earned a Master of Public Administration from the University of Southern California and holds two honorary doctorates.
# # #
About TGen, an affiliate of City of Hope
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based nonprofit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: CityofHope.org. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: tgen.org. Follow TGen on Facebook, LinkedIn and Twitter @TGen.
About City of Hope
City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hope’s translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nation’s “Best Hospitals” in cancer by U.S. News & World Report. Its main campus is located near Los Angeles, with additional locations throughout Southern California and in Arizona. Translational Genomics Research Institute (TGen) became a part of City of Hope in 2016. AccessHopeTM, a subsidiary launched in 2019, serves employers and their health care partners by providing access NCI-designated cancer center expertise. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.